Multisensory signaling using health care, safety, and social media data to automate drug safety surveillance
SAN DIEGO, CA – June 16, 2014 – In its latest deep dive into Pharmacovigilance (PV) trends and the future of life science, ArisGlobal, a leading provider of solutions to the life-sciences industry, sheds light on the emerging areas of proactive Pharmacovigilance and EHR- and social media-driven PV at DIA Annual San Diego on June 18 at 1:30PM – 2:30PM (PST). As part of the “The Role of Intelligent Signaling in Digital Disease Detection and Proactive Pharmacovigilance” session chaired by John S. Brownstein, PhD (Manager and Associate Professor at Boston Children’s Hospital and Harvard Medical School), ArisGlobal’s Ambrish Mathur, Vice President, Strategic Development, will delve into the topic of automating drug safety surveillance using multisensory signaling with health care, safety, and social media data. The session also discusses how social media can make disease data publicly available earlier than traditional surveillance systems, therefore allowing us to limit their impact on communities.
These and other proposed developments in intelligent signaling could not only change the paradigm in modern PV and safety, but also in disease detection and prevention.. The presenters will “…examine how the use of intelligent signaling systems in conjunction with traditional adverse event (AE) data systems can offer an improved automated surveillance system that may assist or even eventually replace manual individual case safety report (ICSR) case assessment” and discuss “… use of social media sources such as Facebook, Twitter, web searches, news reports, chat rooms, etc., to crowd source data regarding disease outbreaks provides an opportunity to monitor, track and, ideally, forecast infectious disease outbreaks.”
“The promise of automated proactive Pharmacovigilance utilizing diverse data sources is so powerful that it can potentially lead to implementation of a process-based “PV machine” that eliminates the tedium of the routine tasks associated with individual case processing and analysis,” said Mr. Mathur.
The session will be conducted on June 18, 1:30PM – 2:30PM (PST), after which Mr.Mathur will be available at booth #1013 to answer questions on the session as well as discuss the present and future of global Pharmacovigilance and safety practices.
The foray into this particular area of PV research continues ArisGlobal’s 25+ year history of Pharmacovigilance and safety innovation including, most recently, delivering the world’s only truly global safety solution (ArisGlobal Total Safety), and winning the prestigious Frost & Sullivan North American Pharmacovigilance Software Customer Value Enhancement Award in recognition of accomplishments, innovation and customer focus in the Pharmacovigilance sector.
For over 25 years ArisGlobal (www.arisglobal.com) has been a leading provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and quality & compliance for medical inquiries. Solutions are available on premise or on a regulated cloud platform. Life science companies using ArisGlobal’s solutions can better build and maintain the trust they need with their customers, medical practitioners and regulatory bodies around the world.
ArisGlobal is exhibiting at DIA Annual San Diego 16th – 19th June with a team of subject matter experts available for interviews.
Tel + 44 0) 7760161041